A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
ID Number 16-1217Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called ASP2215 in treatment for AML patients with mutations in FLT3 gene identified by an investigational FLT3 test using your blood or bone marrow to see if you have a mutations of the FLT3 gene, compared to salvage chemotherapy.
Recruiting Patients: Yes